About Apellis Pharmaceuticals, Inc. Common Stock
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Market Cap
$2.99B
Employees
710
Listed Since
November 9, 2017
Industry
PHARMACEUTICAL PREPARATIONS